New insulin copycat put to the test in healthy volunteers
NCT ID NCT05539872
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a new rapid-acting insulin (called I004) works the same as the approved insulin NovoLog. Sixty-nine healthy volunteers each received a single dose of both insulins at different times, and researchers measured how quickly the insulin entered the blood and how it controlled blood sugar. The goal was to show the new insulin is a "biosimilar" — meaning it is highly similar to NovoLog — not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETICS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amphastar Study Site
Chula Vista, California, 91911, United States